UPDATE: Cantor Fitzgerald Starts Cerevel Therapeutics (CERE) at Overweight

Cantor Fitzgerald initiates coverage on Cerevel Therapeutics (NASDAQ: CERE) with a Overweight rating and a price target of $41.00.

The analyst comments "In valuing CERE, we derive our $41 PT by using a discounted NPV probability adjusted revenue calculation, which yields ~$16/share for emraclidine in schizophrenia (70% probability of success, 70% contribution margin, 20% discount rate), ~$12/share for darigabat in epilepsy (65% probability of success, 70% contribution margin, 20% discount rate) and ~$5/share in panic disorder (60% probability of success, 70% contribution margin, 20% discount rate), ~$3/share for tavapadon (55% and 35% probability of success for early-mid and late-stage PD respectively, 70% contribution margin, 20% discount rate), ~$2/share as a placeholder in CVL-871 and CVL-354, and a $~1/share placeholder in preclinical compounds."

For an analyst ratings summary and ratings history on Cerevel Therapeutics click here. For more ratings news on Cerevel Therapeutics click here.

Shares of Cerevel Therapeutics closed at $28.00 yesterday.

You May Also Be Interested In

• UBS Starts Nuvama Wealth Management (NUVAMA:IN) at Buy
• MYR Group (MYRG) PT Lowered to $422 at Goldman Sachs
• Nomura/Instinet Upgrades Seiko Group Corp (8050:JP) to Buy